liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy
Department of Immunology, Faculty of Biotechnology, Jagiellonian University, Krakow, Poland; Institute of Experimental Dermatology, University of Münster, Münster, Germany.
Department of Medicine/Hematology and Oncology, University of Münster, Münster, Germany.
Department of Immunology, Faculty of Biotechnology, Jagiellonian University, Krakow, Poland.
Manitoba Institute of Cell Biology, and Department of Biochemistry and Medical Genetics, Univ. Manitoba, Winnipeg, Canada.
Show others and affiliations
2005 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 116, no 2, 167-173 p.Article in journal (Refereed) Published
Abstract [en]

Despite significant progress in cancer therapy, the outcome of the treatment is often unfavorable. Better treatment monitoring would not only allow an individual more effective, patient-adjusted therapy, but also it would eliminate some of the side effects. Using a cytochrome c ELISA that was modified to increase sensitivity, we demonstrate that serum cytochrome c is a sensitive apoptotic marker in vivo reflecting therapy-induced cell death burden. Furthermore, increased serum cytochrome c level is a negative prognostic marker. Cancer patients whose serum cytochrome c level was normal 3 years ago have a twice as high probability to be still alive, as judged from sera samples collected for years, analyzed recently and matched with survival data. Moreover, we show that serum cytochrome c and serum LDH-activity reflect different stages and different forms of cell death. Cellular cytochrome c release is specific for apoptosis, whereas increased LDH activity is an indicator of (secondary) necrosis. Whereas serum LDH activity reflects the "global" degree of cell death over a period of time, the sensitive cytochrome c-based method allows confirmation of the individual cancer therapy-induced and spontaneous cell death events. The combination of cytochrome c with tissue-specific markers may provide the foundation for precise monitoring of apoptosis in vivo, by "lab-on-the-chip" technology. (c) 2005 Wiley-Liss, Inc.

Place, publisher, year, edition, pages
2005. Vol. 116, no 2, 167-173 p.
Keyword [en]
activation, Apoptosis, Bcl-2, bystander effect, caspases, cell-death, cytochrome c, family, inhibition, ldh, Mitochondria, necrosis, non-hodgkins-lymphoma, prognostic factor, release, treatment monitoring
National Category
Cancer and Oncology Cell Biology Biochemistry and Molecular Biology
URN: urn:nbn:se:liu:diva-86998DOI: 10.1002/ijc.21037ISI: 000230288300001OAI: diva2:584192
Available from: 2013-01-08 Created: 2013-01-08 Last updated: 2013-09-03

Open Access in DiVA

fulltext(333 kB)234 downloads
File information
File name FULLTEXT01.pdfFile size 333 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Los, Marek Jan
In the same journal
International Journal of Cancer
Cancer and OncologyCell BiologyBiochemistry and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 234 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 77 hits
ReferencesLink to record
Permanent link

Direct link